Top Markets
#1 Black Phoenix Black Phoenix +829.97%
#2 pipedog pipedog +41.42%
#3 PondCoin PondCoin +34.34%
#4 Bless Bless +32.22%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +28.74%
#6 SAFEcoin SAFEcoin +26.51%
#7 Beam Beam +24.69%
#8 Magma Finance Magma Finance +19.36%
#9 Seeker Seeker +19.26%
#10 YFSX YFSX +16.15%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
Rangering i aksjer #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
Aksjekurs
$64.97
Sist synkronisert: 2024-05-20
Markedsverdi
$1.97B
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Alpine Immune Sciences, Inc. (ALPN)

Kategori

Healthcare
Inntekter for Alpine Immune Sciences, Inc. (ALPN)
Inntekter i Mar 2024 TTM: $-36.73M
Ifølge Alpine Immune Sciences, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat $-36.73M. I 2022 hadde selskapet et resultat på $-55.43M, en nedgang sammenlignet med resultatet i 2021, som var $-50.42M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Alpine Immune Sciences, Inc. fra 2012 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-36.73M 14.50%
2023 $-32.08M -42.13%
2022 $-55.43M 9.94%
2021 $-50.42M 80.42%
2020 $-27.95M -33.23%
2019 $-41.85M 13.56%
2018 $-36.85M 361.64%
2017 $-7.98M -74.63%
2016 $-31.46M 37.89%
2015 $-22.82M 51.76%
2014 $-15.04M -7.17%
2013 $-16.20M 69.21%
2012 $-9.57M 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -14,460.11%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -5,410.35%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 10,833.48%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 8,303.89%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH